Compare Enbridge Inc (ENB) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Enbridge Inc trades at $47.5 (market cap $105.81B), while GE HealthCare Technologies Inc. Common Stock trades at $69.4 (market cap $30.93B). The key difference: Enbridge Inc is far larger — about 3.4× GE HealthCare Technologies Inc. Common Stock's market cap, and Enbridge Inc pays the higher dividend (5.91%). Which is the better fit depends on your goals.
| ENB | GEHC | |
|---|---|---|
Market Cap | $105.81B | $30.93B |
Volume | 3,872,535 | 5,033,451 |
Sector | Energy | Health |
52-Week High | $58.04 | $88.16 |
52-Week Low | $45.23 | $59.48 |
Typical Hold Time | 92 Days | — |
Enterprise Value | $188.05B | $39.39B |
Dividend Yield | 5.91% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $47.46, up 1.09% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly earnings beats. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%. Analyst consensus is split between Buy and Hold, with a $61.63 price target suggesting significant upside. The stock offers a 6% dividend yield, supported by stable cash flows from its midstream energy operations.
Outlook is mixed: robust EBITDA growth and strategic expansion into renewables provide long-term value, but rising debt levels and interest rate sensitivity pose risks. Near-term performance may hinge on Q3 2026 earnings versus the $0.38 estimate. Institutional interest remains strong, as seen in Nykredit's $51.75M purchase in September 2026.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
